Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Abdominal Imaging|September 20, 2015
Hot spleen: hypervascular lesions of the spleenMichyla Bowerson, Christine O Menias, Kristen Lee, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|January 29, 2026
Multisystemic Imaging Features of CoccidioidomycosisLogan P Haug, Harrison Lang, Muhammad Naeem, et al.
Abdominal Radiology (New York)|February 3, 2023
Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenariosKaterina S Konstantinoff, Ajaykumar C Morani, Thomas A Hope, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|October 3, 2024
Imaging of Ischemic Cholangiopathy Following Donation after Circulatory Death Liver TransplantMaria Zulfiqar, Mark Sugi, Sudhakar K Venkatesh, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|December 9, 2022
Urinary Bladder Masses, Rare Subtypes, and Masslike Lesions: Radiologic-Pathologic CorrelationMark J Hoegger, Benjamin S Strnad, David H Ballard, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|June 21, 2020
Feasibility and safety of non-operative management of portal vein aneurysms: a thirty-five year experienceOla Ahmed, John W Ohman, Neeta Vachharajani, et al.
Journal of the American College of Radiology : JACR|March 13, 2026
ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors, Joseph H Yacoub, Motoyo Yano, et al.
American Journal of Clinical Oncology|July 2, 2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaShahed N Badiyan, Jeffrey R Olsen, Andrew Y Lee, et al.
Abdominal Radiology (New York)|March 4, 2022
Pancreatic neuroendocrine neoplasms: a 2022 update for radiologistsSamuel J Galgano, Ajaykumar C Morani, Dheeraj R Gopireddy, et al.
The Lancet. Oncology|April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trialTimothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Pageof 6